In November, of the 12 analysts covering Clovis Oncology (CLVS) stock, seven have given it “buy” or higher ratings, and five have given it “hold” ratings.
The FDA’s approval of Clovis Oncology’s (CLVS) Rubraca for the maintenance treatment of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in April was the second and much broader indication the drug has been approved for.
On July 27, Merck (MRK) and AstraZeneca (AZN) announced a strategic global collaboration for co-developing and co-commercializing the latter’s poly ADP ribose polymerase (or PARP) inhibitor, Lynparza.
The S&P 500 Index (SPX-INDEX) has posted a rise of ~5% since the beginning of 2017, with banks and energy stocks leading the rally as of March 29, 2017.
Immunogen rose by 7.2% as of November 25, 2015. The stock rose on the high trading volume. It closed at $13.76. It passed the 100-day moving average price.
Pacira Pharmaceuticals (PCRX) rose 19.5% and closed at $49.12. Pacira had a weight of 0.25% in IBB’s portfolio. It was one of the top performers on October 27.
XBI’s moving average took a hit in the week ended September 25, and most of its stocks were trading below all the moving averages. Compared to the previous week, the fall was massive.
Dyax (DYAX) gained 9.41% last week. The stock went up after Dyax presented at the Morgan Stanley global healthcare conference, which took place September 16-18 in New York.
The SPDR S&P Biotech ETF (XBI) fell 4.53%. It tracks the S&P Biotechnology Select Industry Index as its benchmark index, which fell 4.32% for the week ended September 4.
Out of 62 stocks held within the pharmaceutical subgroup of the iShares NASDAQ Biotechnology ETF (IBB), 49 stocks fell during the week ending August 7, 2015.
For the week ending July 31, the stocks that moved into the 100-day moving average zone include Akorn, Clovis Oncology, Endo International, and Grifols.
